Paul Vigo, MD
Allergy & Immunology · Austin, TXNPI 1518063817
Payments from drug & device makers
Across 993 payments — averaging $305.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$188K
- AstraZeneca$42K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Shire North American Group Inc$20K
- Sanofi$10K
- Regeneron Healthcare Solutions, Inc.$8K
- plus $12K from 34 others
What the payments were for
- Consulting fees$8,8043%
- Speaking & faculty fees$258,21885%
- Travel & lodging$13,8655%
- Food & beverage$22,6907%
- Education$1500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 275 | $188,459 |
| AstraZeneca | 132 | $41,999 |
| Takeda Pharmaceuticals U.S.A., Inc. | 80 | $23,218 |
| Shire North American Group Inc | 38 | $20,072 |
| Sanofi | 85 | $9,631 |
| Regeneron Healthcare Solutions, Inc. | 67 | $8,200 |
| Alk-abello, Inc | 31 | $5,049 |
| Regeneron | 10 | $843 |
| Novartis | 44 | $782 |
| Genentech USA, Inc. | 26 | $695 |
| Amgen | 38 | $676 |
| CSL Behring | 23 | $590 |
| Blueprint Medicines Corporation | 11 | $510 |
| Grifols USA, LLC | 22 | $463 |
| Pfizer | 18 | $352 |
| Boehringer Ingelheim | 14 | $270 |
| Teva Pharmaceuticals USA, Inc. | 10 | $267 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $228 |
| Kaleo, Inc. | 10 | $191 |
| Octapharma USA, Inc. | 6 | $184 |
| Galderma Laboratories, L.p. | 5 | $152 |
| Mylan Specialty L.p. | 11 | $150 |
| AbbVie | 1 | $126 |
| Pharming Healthcare, Inc. | 3 | $84 |
| Verona Pharma, Inc. | 3 | $77 |
| LEO Pharma Inc. | 3 | $73 |
| Philips North America LLC | 4 | $71 |
| Covis Pharma GmbH | 2 | $50 |
| ADMA Biomanufacturing LLC | 2 | $37 |
| Insmed, Inc. | 2 | $36 |
| Biocryst US Sales Co., LLC | 2 | $34 |
| Kedrion Biopharma, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| GC Biopharma USA, Inc. | 1 | $17 |
| Hospira, Inc. | 1 | $16 |
| GE HealthCare | 1 | $15 |
| Organon | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$303,727 in reported general payments places this provider in the 95th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyqviaIgg/Hyaluronidase,recombinant | 26 | $108,297 |
| Dupixent PenDupilumab | 20 | $75,911 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,353 |
| Epinephrine | 35 | $8,987 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $3,025 |
| Azelastine Hcl | 43 | $1,475 |
| Ipratropium Bromide | 33 | $1,157 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $451 |
| Montelukast Sodium | 56 | $358 |
| Prednisone | 13 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $23,218 | $108,29726 claims |
| GSKTrelegy Ellipta | $188,459 | $16,35326 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $8,98735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Austin
- William HowlandAustin$3.6M
- Neha ReshamwalaAustin$359K
- Allen LiebermanAustin$227K
- Michael VolzAustin$78K
- William OttoAustin$48K
- Stacy SilversAustin$30K
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
- Lyndon MansfieldEl Paso$2.4M
- Dale MoharKerrville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.